肿瘤生育保护治疗致卵巢18F-FDG高摄取误判为盆腔淋巴瘤一例
一例23岁原发纵隔大B细胞淋巴瘤女性患者行18F-FDG PET/CT分期,盆腔发现FDG高摄取病灶(SUV高于黄体囊肿常见水平),疑为肿瘤。经妇科超声及病史复核,确认为促性腺激素释放激素(GNRH)类似物肿瘤生育保护治疗所致左卵巢强烈摄取,疾病降期为II期,治疗强度随之降低。
要点
- GNRH类似物肿瘤生育保护治疗可致卵巢18F-FDG摄取明显高于月经周期常见SUV水平。
- 育龄女性淋巴瘤18F-FDG PET/CT盆腔高摄取灶应结合妇科超声与用药史鉴别,避免误判为肿瘤。
- 排除生理或治疗相关摄取后,本例疾病降期为II期并采用强度较低的治疗。
核心结论
- GNRH类似物肿瘤生育保护治疗可引起左卵巢强烈18F-FDG摄取,SUV远高于月经周期常见水平,易被误判为盆腔淋巴瘤而致分期上调。
研究设计与样本
- 个案报道:一例23岁原发纵隔大B细胞淋巴瘤女性患者行18F-FDG PET/CT分期检查。
主要发现
- 除纵隔FDG高摄取大肿块外,盆腔另见FDG高摄取病灶,SUV高于黄体囊肿预期水平,最初怀疑为肿瘤。
- 妇科超声与病历复核显示患者有GNRH类似物肿瘤生育保护治疗史,该治疗是左卵巢强烈FDG摄取的原因。
- 明确为治疗相关摄取后,疾病降期为II期,治疗强度降低。
临床怎么用
- 育龄女性淋巴瘤患者18F-FDG PET/CT见盆腔FDG高摄取灶时,应询问肿瘤生育保护治疗史并结合妇科超声,避免误判为肿瘤导致分期上调。
局限性
- 为单例个案报道,结论的普遍适用性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 23-year-old woman with primary mediastinal large B-cell lymphoma was referred to 18F-FDG PET/CT for staging. Besides the large mediastinal FDG-avid tumor, another FDG-avid lesion with an SUV higher than expected in corpus luteum cysts was found in the pelvis, raising suspicion for tumor. However, gynecologic ultrasound and review of patient chart revealed history of oncofertility treatment with GNRH analog. This prior treatment was responsible for the intense 18F-FDG uptake within the left ovary, way above the SUV levels commonly associated with menstrual cycle. In this case, the disease was downgraded to stage II, resulting in a less aggressive treatment.
引用
- Schierz JH, Ali F, McLeod A, et al. Risk of Upstaging Due to Oncofertility Treatment Mimicking Pelvic Lymphoma on 18F-FDG PET/CT. Clin Nucl Med. 2022. PMID: 34690290. doi:10.1097/RLU.0000000000003945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。